Angela Zubel
Universitat Autònoma de Barcelona(ES)Novartis (Switzerland)(CH)The University of Texas MD Anderson Cancer Center(US)University of California, Los Angeles(US)Princess Margaret Cancer Centre(CA)Institute of Oncology Research(CH)GlaxoSmithKline (United States)(US)Hospital Universitario Virgen del Rocío(ES)KU Leuven(BE)
Publications by Year
Research Areas
Colorectal Cancer Treatments and Studies, Lung Cancer Treatments and Mutations, HER2/EGFR in Cancer Research, Cancer Treatment and Pharmacology, Melanoma and MAPK Pathways
Most-Cited Works
- → Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status(2011)1,880 cited
- → Fluorouracil, Leucovorin, and Oxaliplatin With and Without Cetuximab in the First-Line Treatment of Metastatic Colorectal Cancer(2008)1,636 cited
- → EPIC: Phase III Trial of Cetuximab Plus Irinotecan After Fluoropyrimidine and Oxaliplatin Failure in Patients With Metastatic Colorectal Cancer(2008)949 cited
- → Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study(2011)779 cited
- → MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study(2013)639 cited
- →